Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations
Noelia Martínez-Jáñez(Instituto Cajal), Miguel Quintela-Fandiño(Spanish National Cancer Research Centre)
Cited by 3
Related Papers
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
|Journal of Clinical Oncology|2006|149
Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells
|Nature Communications|2019|66
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
|Nature Communications|2018|55
Toxicity of prolonged treatment with eribulin (E) in metastatic breast cancer (MBC) patients: Results of the EXTER study.
|Journal of Clinical Oncology|2015|0